Monte Rosa Therapeutics
GLUEClinical Pipeline
Program / Asset
Target Indications
Development Phase
Financial Statements & Analysis
Total Gross Revenue
— — — —
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
($30.65M) ($36.68M) ($141.50M) ($44.07M)
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($8.10M) ($9.06M) ($36.38M) ($10.18M)
Operating Income / (Loss)
($15.55M) ($32.98M) ($54.21M) ($50.03M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
— — — —
Interest & Debt Servicing Expense
— — — —
Other Non-Operating Income / (Expense)
$4.46M $2.72M $14.48M $5.58M
Income Tax Provision / (Benefit)
$1.20M ($3.18M) ($1.10M) $0.05M
NET INCOME / (NET LOSS)
($12.29M) ($27.08M) ($38.60M) ($44.50M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$69.4M$208.3M$129.9M$159.9M
Short-Term Marketable Investments
// --// --// --// --
Total Liquid Cash Resources
$69.4M$208.3M$129.9M$159.9M
Accounts Receivable, Net
// --// --// --// --
Prepaid Expenses & Other Current Assets
$6.5M$5.6M$4.5M$6.7M
Total Current Assets
$299.5M$401.8M$393.2M$677.5M
Property, Plant and Equipment, Net
$29.1M$27.6M$26.0M$28.4M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$359.6M$459.8M$448.7M$736.4M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
$5.6M$14.5M$3.5M$7.9M
Accrued Expenses & Clinical Liabilities
$5.1M$7.3M$26.7M$25.6M
Total Current Liabilities
$41.9M$61.4M$64.2M$71.0M
Long-Term Corporate Debt Balances
// --// --// --// --
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$49.7M$152.6M$151.4M$143.5M
Total Liabilities Block
$91.5M$214.0M$215.6M$214.5M
Total Stockholders' Equity
$268.1M$245.8M$233.1M$521.9M
TOTAL LIABILITIES & EQUITY
$359.6M$459.8M$448.7M$736.4M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
7.16x 6.54x 6.12x 9.54x
R&D Expenditure Flow
$62.8M$99.5M$141.5M$44.1M
Net Income / (Loss)
($12.29M) ($27.08M) ($38.60M) ($44.50M)
Depreciation & Amortization
$2.13M $2.10M $8.36M $2.03M
Stock-Based Compensation
$10.19M $14.56M $18.86M $5.95M
Change in Accounts Receivable
$0.00M — — —
Change in Prepaid Assets / Expenses
$1.71M $0.77M ($0.60M) $2.92M
Change in Payables & Clinical Accruals
($11.98M) ($3.10M) ($13.71M) $4.38M
Other Operating Source / (Use) Changes
($69.97M) $32.97M $2.89M ($8.14M)
Net Cash from Operating Activities
($80.21M) $20.22M ($22.80M) ($37.37M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
($3.28M) ($3.93M) ($4.70M) ($1.87M)
Purchases of Marketable Securities
($157.05M) ($223.02M) ($376.68M) ($332.00M)
Maturities & Sales of Investments
— — — —
Net Cash from Investing Activities
($74.91M) ($36.77M) ($101.83M) ($261.00M)
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
$0.00M $0.00M — —
Net Cash from Financing Activities
$0.38M $0.73M $30.35M $328.33M
NET CONSOLIDATED CHANGE IN CASH
($154.74M) ($15.82M) ($94.28M) $29.97M
Clinical Trials Registry
Registry ID
Phase / Asset
Status